P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coff...(ding with respect to lower incomeconsume...),Health

Date:1/31/2008

ding with respect to lower income consumers and growing existing sales and volume profitably despite high levels of competitive activity, especially with respect to the product categories and geographical markets (including developing markets) in which the Company has chosen to focus; (2) the ability to successfully execute, manage and integrate key acquisitions and mergers, including (i) the Domination and Profit Transfer Agreement with Wella, and (ii) the Company's merger with The Gillette Company, and to achieve the cost and growth synergies in accordance with the stated goals of these transactions; (3) the ability to manage and maintain key customer relationships; (4) the ability to maintain key manufacturing and supply sources (including sole supplier and plant manufacturing sources); (5) the ability to successfully manage regulatory, tax and legal matters (including product liability, patent, and intellectual property matters as well as those related to the integration of Gillette and its subsidiaries), and to resolve pending matters within current estimates; (6) the ability to successfully implement, achieve and sustain cost improvement plans in manufacturing and overhead areas, including the Company's outsourcing projects; (7) the ability to successfully manage currency (including currency issues in volatile countries), debt, interest rate and commodity cost exposures; (8) the ability to manage continued global political and/or economic uncertainty and disruptions, especially in the Company's significant geographical markets, as well as any political and/or economic uncertainty and disruptions due to terrorist activities; (9) the ability to successfully manage competitive factors, including prices, promotional incentives and trade terms for products; (10) the ability to obtain patents and respond to technological advances attained by competitors and patents granted to competitors; (11) the ability to successfully manage increases in the prices of raw materia
'/>"/>

SOURCE The Procter & Gamble Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine news :

1. Nutraceutical Reports Fiscal 2008 Q1 Results
2. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
3. Accuray Reports Continued Growth in Second Quarter of Fiscal 2008
4. Cardinal Health Reports Second Quarter Results, Revises EPS Outlook
5. Encision Reports Third Fiscal Quarter Results
6. Zimmer Reports Fourth Quarter and 2007 Financial Results
7. Amylin Pharmaceuticals Reports 2007 Financial Results
8. Cystic Fibrosis Foundation reports upward trend for key health outcomes
9. NBTY Reports First Quarter Results
10. Moog Reports 14% Increase in Earnings Per Share
11. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million